Fetal Hemoglobin Induction Treatment Metformin

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

March 2, 2017

Primary Completion Date

July 20, 2020

Study Completion Date

July 20, 2020

Conditions
Sickle Cell AnemiaSickle Cell DiseaseHemoglobin Disorder
Interventions
DRUG

Metformin

Metfomin will be taken daily. The metformin dose will be increased during two time points per subject if protocol dose escalation criteria is met.

BEHAVIORAL

Questionnaires

Questionnaires will be completed to assess the impact quality of life

Trial Locations (2)

77030

Texas Children's Hospital, Houston

The University of Texas Health Science Center at Houston, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Baylor College of Medicine

OTHER

NCT02981329 - Fetal Hemoglobin Induction Treatment Metformin | Biotech Hunter | Biotech Hunter